JERSEY CITY, N.J., April 10, 2018 /PRNewswire/ -- SCYNEXIS, Inc.
(NASDAQ: SCYX), a biotechnology company delivering innovative
anti-infective therapies for difficult-to-treat and often
life-threatening infections, today announced three poster
presentations at the 28th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID), April 21-24, 2018, in Madrid, Spain. SCY-078, the first
representative of a novel oral and intravenous (IV) triterpenoid
antifungal family, is in clinical development for the treatment of
several serious fungal infections, including vulvovaginal
candidiasis, invasive candidiasis, invasive aspergillosis and
refractory invasive fungal infections.
Title: In Vitro Activity of SCY-078, a
Novel IV/Oral Glucan Synthase Inhibitor, against Aspergillus
spp., Alone or in Combination with other Antifungal
Therapies
Presenter: Mahmoud Ghannoum PhD
Date and Time: Saturday, April
21, from 15:30-16:30 CET
Poster Presentation #: PO164
Session: Aspergillus in the laboratory
Title: Activity of SCY-078 and comparators against a
collection of Aspergillus spp. including cryptic species and
Cyp51A mutants
Presenter: Ana Alastruey-Izquierdo PhD
Date and Time: Saturday, April
21, from 15:30-16:30 CET
Poster Presentation #: PO165
Session: Aspergillus in the laboratory
Title: SCY-078 Demonstrates Antifungal Activity Against
Pneumocystis in a Prophylactic Murine Model of
Pneumocystis Pneumonia
Presenter: Stephen Barat PhD
Date and Time: Sunday, April
22, from 13:30-14:30 CET
Poster Presentation #: P1226
Session: Update on Pneumocystis
The ECCMID 2018 posters will be available on the SCYNEXIS
website following the event.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a
biotechnology company committed to positively impacting the lives
of patients suffering from difficult-to-treat and often
life-threatening infections by delivering innovative anti-infective
therapies. The SCYNEXIS team has extensive
experience in the life sciences industry, discovering and
developing more than 30 innovative medicines over a broad range of
therapeutic areas. The Company's lead product
candidate, SCY-078, is a novel IV/oral antifungal agent in
Phase 2 clinical and preclinical development for the treatment of
several serious and life-threatening invasive fungal infections
caused
by Candida and Aspergillus species.
For more information, visit www.scynexis.com.
CONTACT:
Investor
Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com
Media Relations
George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093
george@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/scynexis-to-present-scy-078-data-at-the-28th-european-congress-of-clinical-microbiology-and-infectious-disease-eccmid-300625304.html
SOURCE SCYNEXIS, Inc.